scholarly journals Human mammary tumor virus in inflammatory breast cancer

Cancer ◽  
2010 ◽  
Vol 116 (S11) ◽  
pp. 2741-2744 ◽  
Author(s):  
Beatriz G.-T. Pogo ◽  
James F. Holland ◽  
Paul H. Levine
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Mammary Tumor ◽  
Mammary Tumor Virus ◽  
Tumor Virus ◽  
Human Mammary Tumor Virus

scholarly journals Low prevalence of human mammary tumor virus (HMTV) in breast cancer patients from Myanmar

2017 ◽  
Vol 12 (1) ◽  
Author(s):  
Thar Htet San ◽  
Masayoshi Fujisawa ◽  
Soichiro Fushimi ◽  
Teizo Yoshimura ◽  
Toshiaki Ohara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Mammary Tumor ◽  
Breast Cancer Patients ◽  
Mammary Tumor Virus ◽  
Tumor Virus ◽  
Low Prevalence ◽  
Human Mammary Tumor Virus

Abstract 4062: Human mammary tumor virus (HMTV) is a breast cancer pathogen

2016 ◽  
Author(s):  
James F. Holland ◽  
Stella Melana ◽  
Teiko Nartey ◽  
Joseph Tripodi ◽  
Shabnam Jaffer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mammary Tumor ◽  
Mammary Tumor Virus ◽  
Tumor Virus ◽  
Human Mammary Tumor Virus

Detection of human mammary tumor virus proteins in human breast cancer cells

2010 ◽  
Vol 163 (1) ◽  
pp. 157-161 ◽  
Author(s):  
Stella M. Melana ◽  
Irene Nepomnaschy ◽  
Jennifer Hasa ◽  
Alina Djougarian ◽  
Anna Djougarian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Mammary Tumor ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Mammary Tumor Virus ◽  
Tumor Virus ◽  
Human Mammary Tumor Virus

Abstract 821: Human mammary tumor virus(HMTV) is deeply involved in breast cancer and metastasis

2015 ◽  
Author(s):  
James F. Holland ◽  
Stella Melana ◽  
Shabnam Jaffer ◽  
Polly Etkind ◽  
Teiko Nartey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mammary Tumor ◽  
Mammary Tumor Virus ◽  
Tumor Virus ◽  
Human Mammary Tumor Virus

scholarly journals Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth

2015 ◽  
Vol 29 (10) ◽  
pp. 1468-1485 ◽  
Author(s):  
Cecilia J. Proietti ◽  
Franco Izzo ◽  
María Celeste Díaz Flaqué ◽  
Rosalía Cordo Russo ◽  
Leandro Venturutti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Signaling Pathways ◽  
Mammary Tumor ◽  
Mouse Mammary Tumor Virus ◽  
Cancer Growth ◽  
Mammary Tumor Virus ◽  
Mouse Mammary Tumor ◽  
Tumor Virus ◽  
Virus Promoter

Abstract Accumulated findings have demonstrated the presence of bidirectional interactions between progesterone receptor (PR) and the ErbB family of receptor tyrosine kinases signaling pathways in breast cancer. We previously revealed signal transducer and activator of transcription 3 (Stat3) as a nodal convergence point between said signaling pathways proving that Stat3 is activated by one of the ErbBs' ligands, heregulin (HRG)β1 via ErbB2 and through the co-option of PR as a signaling molecule. Here, we found that HRGβ1 induced Stat3 recruitment to the promoters of the progestin-regulated cell cycle modulators Bcl-XL and p21CIP1 and also stimulated Stat3 binding to the mouse mammary tumor virus promoter, which carries consensus progesterone response elements. Interestingly, HRGβ1-activated Stat3 displayed differential functions on PR activity depending on the promoter bound. Indeed, Stat3 was required for PR binding in bcl-X, p21CIP1, and c-myc promoters while exerting a PR coactivator function on the mouse mammary tumor virus promoter. Stat3 also proved to be necessary for HRGβ1-induced in vivo tumor growth. Our results endow Stat3 a novel function as a coregulator of HRGβ1-activated PR to promote breast cancer growth. These findings underscore the importance of understanding the complex interactions between PR and other regulatory factors, such as Stat3, that contribute to determine the context-dependent transcriptional actions of PR.

A Mouse Mammary Tumor Virus-Like Long Terminal Repeat Superantigen in Human Breast Cancer

2004 ◽  
Vol 64 (12) ◽  
pp. 4105-4111 ◽  
Author(s):  
Yue Wang ◽  
Jian-Dong Jiang ◽  
Dongping Xu ◽  
Yan Li ◽  
Chunfeng Qu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Long Terminal Repeat ◽  
Mammary Tumor ◽  
Mouse Mammary Tumor Virus ◽  
Human Breast Cancer ◽  
Terminal Repeat ◽  
Human Breast ◽  
Mammary Tumor Virus ◽  
Mouse Mammary Tumor ◽  
Tumor Virus

scholarly journals Seroprevalence of Human Betaretrovirus Surface Protein Antibodies in Patients with Breast Cancer and Liver Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-9 ◽  
Author(s):  
Guangzhi Zhang ◽  
Kiandokht Bashiri ◽  
Mark Kneteman ◽  
Kevan Cave ◽  
Youngkee Hong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Disease ◽  
Mammary Tumor ◽  
Inflammatory Diseases ◽  
Standard Technique ◽  
Primary Biliary Cholangitis ◽  
Breast Cancer Patients ◽  
Mammary Tumor Virus ◽  
Retroviral Infection ◽  
Tumor Virus

Mouse mammary tumor virus (MMTV) is a betaretrovirus that plays a causal role in the development of breast cancer and lymphoma in mice. Closely related sequences that share 91–99% nucleotide identity with MMTV have been repeatedly found in humans with neoplastic and inflammatory diseases. Evidence for infection with a betaretrovirus has been found in patients with breast cancer and primary biliary cholangitis and referred to as the human mammary tumor virus and the human betaretrovirus (HBRV), respectively. Using the gold standard technique of demonstrating retroviral infection, HBRV proviral integrations have been detected in cholangiocytes, lymph nodes, and liver of patients with primary biliary cholangitis. However, the scientific biomedical community has not embraced the hypothesis that MMTV like betaretroviruses may infect humans because reports of viral detection have been inconsistent and robust diagnostic assays are lacking. Specifically, prior serological assays using MMTV proteins have produced divergent results in human disease. Accordingly, a partial HBRV surface (Su) construct was transfected into HEK293 to create an ELISA. The secreted HBRV gp52 Su protein was then used to screen for serological responses in patients with breast cancer and liver disease. A greater proportion of breast cancer patients (n = 98) were found to have serological reactivity to HBRV Su as compared to age- and sex-matched control subjects (10.2% versus 2.0%, P=0.017, OR = 5.6 [1.25–26.3]). Similarly, the frequency of HBRV Su reactivity was higher in patients with primary biliary cholangitis (n  =  156) as compared to blood donors (11.5% vs. 3.1%, P=0.0024, OR = 4.09 [1.66–10.1]). While the sensitivity of the HBRV Su ELISA was limited, the assay was highly specific for serologic detection in patients with breast cancer or primary biliary cholangitis, respectively (98.0% [93.1%–99.7%] and 97.0% [93.4%–98.6%]). Additional assays will be required to link immune response to betaretrovirus infection and either breast cancer or primary biliary cholangitis.

Sign in / Sign up

Export Citation Format

Share Document